


Open Synthesis Network (OSN)



OPEN SYNTHESIS NETWORK – CROWD-SOURCING COMPOUND SYNTHESIS

The Open Synthesis Network (OSN) is an innovative project launched by DNDi and partner universities in 2016 to harness the capacity of chemistry teaching labs to help discover new drugs for patients living with neglected diseases. OSN carries out collaborative, early-stage research with master's and undergraduate students, while furthering their understanding of drug discovery and medicinal chemistry.

Students are given real problems from selected DNDi lead optimization programmes, rather than the more traditional synthesis

of well-known substances such as aspirin, as is usual in chemistry teaching labs. Students at partner universities are currently working on compounds that target *Leishmania donovani* and *Leishmania infantum*, the parasites that cause visceral leishmaniasis, as well as compounds focused on *Trypanosoma cruzi*, the causative agent of Chagas disease.

With the addition of eight new partners in 2018, the OSN now comprises 18 universities in Brazil, Germany, India, Switzerland, the UK, and the USA.

Any successful compounds that come from the OSN project will be evaluated further as part of DNDi's discovery pipeline, with the goal of developing oral drugs that are easy to administer and have fewer side effects than existing treatments.

All work generated by OSN will be published in the public domain in real time and remain free of intellectual property (IP). All OSN participants, DNDi included, agree not to take any IP position on any of the data or compounds generated by the projects.